Raises FY25 revenue view to 4.53B yen from 4.5B yen. The company said, “Takeda (TAK) has updated its full year Management Guidance for Revenue primarily due to VYVANSE and raised full year forecasts to reflect cost discipline and FX tailwind.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
- Takeda Advances Zasocitinib Phase 3 Trial in Psoriatic Arthritis: What Investors Should Know
- Takeda’s Phase 3 Mezagitamab Trial in ITP Moves Forward, Keeping Pipeline Hopes in Focus
- Takeda’s TAK-330 Nears Key Milestones in High-Stakes Emergency Surgery Trial
- TAK Earnings Report this Week: Is It a Buy, Ahead of Earnings?